eligibility_summary
Adults 18–75 with advanced solid tumors (preferably gastric/pancreatic) after ≥2 lines, NKG2DL/CLDN18.2 IHC+ (combined score ≥5 on recent tissue), measurable disease, ECOG 0–1, life ≥3 mo, adequate counts/organ function, apheresis feasible, contraception. Exclude active HIV/HBV/HCV or uncontrolled infection, autoimmune/transplant/immunosuppression, major cardiac/CNS disease, symptomatic brain mets, other malignancy, GI bleed/ulcer, recent therapy (<3 w), prior CAR‑T/TCR‑T, pregnancy, unresolved >G1 AEs, live vaccine, severe allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06134960 tests KD-496, an autologous, genetically modified CAR-T cell therapy engineered to dual-target NKG2D ligands (NKG2DL, e.g., MICA/MICB/ULBP family) and CLDN18.2 on solid tumors. Drug type: cellular gene therapy (CAR-T). Mechanism: the CAR endows patient T cells with receptors that bind CLDN18.2 and stress-induced NKG2D ligands on tumor cells, triggering T-cell activation and cytotoxic killing (perforin/granzyme, cytokines), aiming to enhance recognition and limit antigen escape. Targets/pathways: tumor cells expressing CLDN18.2 (a tight junction claudin isoform enriched in gastric/pancreatic cancers) and the NKG2D–NKG2DL immune surveillance axis. Indication: advanced NKG2DL+/CLDN18.2+ solid tumors, prioritizing gastric and pancreatic cancers. Phase 1, single-arm, open-label.